Alphabet’s AI drug discovery company Isomorphic Labs has raised $5 billion, its second billion-dollar funding round in six months. Greenoaks and Sequoia Capital co-led the round. New backer Andreessen Horowitz joined Alphabet and all existing investors.
Isomorphic Labs raised $2.1 billion in May 2026. It plans to use the new funding to advance its in-house platform, IsoDDE, and move its drug pipeline toward clinical trials.
IsoDDE aims to improve drug design predictions
IsoDDE stands for Isomorphic Drug Design Engine. According to Isomorphic Labs, it goes beyond AlphaFold 3 and aims to better predict drug binding and docking sites. The company was founded in 2021.
Isomorphic Labs works with Novartis, Eli Lilly, and Johnson & Johnson. It has no approved drug yet. The size of the round puts substantial funding behind a platform and drug pipeline still being developed.

Hassabis took a new role at Alphabet
Demis Hassabis leads Isomorphic Labs. He stepped down from day-to-day leadership of Google Deepmind in August 2026 and now serves as Alphabet’s Chief Scientist. Hassabis and John Jumper won the 2024 Nobel Prize in Chemistry for their work on AlphaFold.
Deepmind disbanded its original AlphaFold team in July 2026. Many researchers moved to Isomorphic Labs or were reassigned to other projects. Nearly a quarter left Deepmind entirely.
Deepmind released AlphaGenome 2 in early November 2026. It predicts how DNA variants affect gene activity in specific cell types. Isomorphic Labs’ next stated step is to advance IsoDDE and push its drug pipeline toward clinical trials.



